Axiom Investors LLC DE Lowers Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Axiom Investors LLC DE lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 96,850 shares of the medical equipment provider’s stock after selling 4,922 shares during the period. Axiom Investors LLC DE’s holdings in Lantheus were worth $8,664,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new stake in Lantheus in the third quarter worth $25,000. Kestra Investment Management LLC bought a new stake in Lantheus in the fourth quarter valued at $27,000. Summit Securities Group LLC purchased a new position in shares of Lantheus during the fourth quarter valued at about $37,000. UMB Bank n.a. raised its position in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after acquiring an additional 134 shares in the last quarter. Finally, Parkside Financial Bank & Trust lifted its position in Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after buying an additional 280 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Insider Transactions at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock valued at $6,110,806 in the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Price Performance

Shares of LNTH stock opened at $96.16 on Monday. The stock’s fifty day moving average price is $93.21 and its 200 day moving average price is $96.38. Lantheus Holdings, Inc. has a 1-year low of $58.16 and a 1-year high of $126.89. The company has a market cap of $6.59 billion, a price-to-earnings ratio of 16.00 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of analyst reports. The Goldman Sachs Group initiated coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial upped their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Finally, B. Riley lowered their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.